Metrovacesa Balance Sheet Health
Financial Health criteria checks 4/6
Metrovacesa has a total shareholder equity of €1.6B and total debt of €435.0M, which brings its debt-to-equity ratio to 26.6%. Its total assets and total liabilities are €2.5B and €874.7M respectively. Metrovacesa's EBIT is €93.0M making its interest coverage ratio 4.7. It has cash and short-term investments of €163.1M.
Key information
26.6%
Debt to equity ratio
€434.96m
Debt
| Interest coverage ratio | 4.7x |
| Cash | €163.13m |
| Equity | €1.63b |
| Total liabilities | €874.73m |
| Total assets | €2.51b |
Recent financial health updates
We Think Metrovacesa (BME:MVC) Can Stay On Top Of Its Debt
May 01
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Nov 05These 4 Measures Indicate That Metrovacesa (BME:MVC) Is Using Debt Extensively
Jul 05Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Dec 02Would Metrovacesa (BME:MVC) Be Better Off With Less Debt?
Feb 16Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Oct 05Recent updates
An Intrinsic Calculation For Metrovacesa S.A. (BME:MVC) Suggests It's 44% Undervalued
Dec 13Estimating The Fair Value Of Metrovacesa S.A. (BME:MVC)
Sep 12We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve
Aug 01Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?
Jul 17A Look At The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)
May 28We Think Metrovacesa (BME:MVC) Can Stay On Top Of Its Debt
May 01Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?
Mar 27A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)
Feb 12Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Nov 05These 4 Measures Indicate That Metrovacesa (BME:MVC) Is Using Debt Extensively
Jul 05Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?
May 21Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)
Apr 19Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Dec 02Is It Too Late To Consider Buying Metrovacesa S.A. (BME:MVC)?
Sep 23Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)
May 19Metrovacesa's (BME:MVC) Strong Earnings Are Of Good Quality
Mar 05Would Metrovacesa (BME:MVC) Be Better Off With Less Debt?
Feb 16Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Oct 05Is Metrovacesa S.A. (BME:MVC) Worth €6.7 Based On Its Intrinsic Value?
Jul 02Is Metrovacesa (BME:MVC) Using Too Much Debt?
May 06Is Metrovacesa S.A. (BME:MVC) A Strong Dividend Stock?
Apr 06Metrovacesa (BME:MVC) Share Prices Have Dropped 51% In The Last Three Years
Mar 15Loss-Making Metrovacesa S.A. (BME:MVC) Set To Breakeven
Feb 16When Should You Buy Metrovacesa S.A. (BME:MVC)?
Jan 26
A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)
Jan 05If You Had Bought Metrovacesa's (BME:MVC) Shares A Year Ago You Would Be Down 24%
Dec 14Financial Position Analysis
Short Term Liabilities: MVC's short term assets (€2.1B) exceed its short term liabilities (€598.4M).
Long Term Liabilities: MVC's short term assets (€2.1B) exceed its long term liabilities (€276.4M).
Debt to Equity History and Analysis
Debt Level: MVC's net debt to equity ratio (16.6%) is considered satisfactory.
Reducing Debt: MVC's debt to equity ratio has increased from 5.1% to 26.6% over the past 5 years.
Debt Coverage: MVC's debt is not well covered by operating cash flow (12.5%).
Interest Coverage: MVC's interest payments on its debt are well covered by EBIT (4.7x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:03 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Metrovacesa S.A. is covered by 25 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Javier Hombría | Ahorro Corporación |
| Pierre-Loup Etienne | AlphaValue |
| Filipe Leite | Banco BPI, S.A. |